Methods for predicting multi-organ metastatic disease and overall and progression free survival in subjects having hyper-engorged circulating cancer associated macrophage-like cells (camls)
AssigneeCreatv Micro Tech, Inc.
InventorsDaniel L. Adams, Cha-Mei TANG
Life of this patent
Estimating the term…
Abstract
Means for predicting (i) multiple organ metastasis and/or multifocal metastatic disease and (ii) overall survival (OS) and progression free survival (PFS) of subjects having cancer are disclosed, where the predictions are based on the number and size of circulating cancer associated macrophage-like cells (CAMLs) found in a biological sample, such as blood, from the subject.
Claims19
A method for diagnosing multiple organ metastasis and/or multifocal metastatic disease in a subject, said method comprising determining the size of CAMLs in a biological sample from a subject, such as a subject having cancer, wherein when at least one CAML in said sample is about 100 μm or more in size, the subject is diagnosed to have multiple organ metastases and/or multifocal metastatic disease.
A method for predicting development of multiple organ metastasis and/or multifocal metastatic disease in a subject, said method comprising determining the size of CAMLs in a biological sample from a subject, such as a subject having cancer, wherein when at least one CAML in said sample is about 100 μm or more in size, the subject is predicted to develop multiple organ metastases and/or multifocal metastatic disease.
A method for predicting overall survival (OS) and/or progression free survival (PFS) of a subject having cancer, said method comprising determining the size of CAMLs in a biological sample from a subject having cancer, wherein when at least one CAML in said sample is about 100 μm or more in size, the subject is predicted to have shorter OS and/or shorter PFS than a subject having the same or similar cancer but lacking at least one CAML in a corresponding sample about 100 μm or more in size.
A method for predicting OS and/or PFS of a subject having cancer, said method comprising determining the size of CAMLs in a biological sample from a subject having cancer, wherein when at least one CAML in said sample is about 100 μm or more in size, the OS and/or PFS of the subject is predicted to be less or shorter than a subject having cancer where none of the CAMLs is more than about 100 μm in size.
Dependencies are inferred from the claim text.